The research presented in the article delves into the regulatory role of the long non-coding RNA (lncRNA) ZNF593-AS in cardiac hypertrophy and myocardial remodeling, processes that are pivotal in the progression of heart failure and other cardiovascular diseases. The study uncovers how ZNF593-AS exerts its inhibitory effects by upregulating the expression of Mitofusin 2 (Mfn2), a protein known for its role in the regulation of mitochondrial dynamics and cellular metabolism.
After Cassava Alzheimer’s drug fiasco, the FDA must intervene to protect patients
For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is
October 2, 2024